|
|
Article: California Stem Cell and Stemina Biomarker Discovery Announce Collaboration to Validate Effectiveness of Human Embryonic Stem Cell-Derived Cardiomyocyte Progenitors for Use in Predictive Toxicology.
- Article from:
- Biotech Week
- Article date:
- September 30, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Collaboration between California Stem Cell, Inc. (CSC) and Stemina Biomarker Discovery on a study using CSC's 96-well CardioPlateTM containing high purity human embryonic stem cell (hESC)-derived cardiomyocyte progenitor cells, has demonstrated that it can be used as a model system for investigating and predicting drug induced cardiotoxicity, officials from the firms announced (see also California Stem Cell, Inc.).
Stemina is a Madison, Wisconsin-based metabolomics company focused on the discovery, development and commercialization of molecular biomarkers to improve drug safety and human health. The firm's cell-based assays study the response of hESCs and ...
Related newspaper, magazine, and journal articles:
|
|
Article: California Stem Cell, Inc. and Families of ...
Business Wire;
October 14, 2009 ;
700+ words
... ... Trials IRVINE, Calif. -- California Stem Cell, Inc. (CSC) and Families ... families and patients. About California Stem Cell, Inc (www.californiastemcell.com) California Stem Cell, Inc is a privately held ...
|
|